High Potency Active Pharmaceutical Ingredients Bolsters Growth of Pharmaceutical Sector for Increasing Therapeutic Applications


Published Date : Apr 01, 2016

In the gamut of pharmacologically active ingredients known for their efficacy, high potency active pharmaceutical ingredients (HPAPIs) are significant. This is because of reasons of significant efficiency and require a low dosage on an everyday basis due to their highly selective action mode. This efficiency of HPAPIs is promoted due to their ability to inhibit specific enzymes or bind to specific receptors. 

Presently, HPAPI is the most swiftly developing segments in the pharmaceutical industry, which exhibits an astoundingly high growth rate. This is because of the high application rate of HPAPIs in the making of highly potent drugs and their ability to target disease cells accurately.

Some of the key trends observed in the HPAPI market are as follows:

  • HPAPIs to Appear as Vital Components in Product Portfolios: Being a key niche segment and on account of its target release characteristics, HPAPI is utilized for target therapies for cancer and hormonal replacements, both of which are high revenue segments within the pharmaceutical industry. Other than this, HPAPIs also find applications in musculoskeletal drugs, central nervous system, and cardiovascular system drug therapies.

Over the last decade, the number of individuals diagnosed with lifestyle diseases such as cancer has risen exponentially. This has been the reason for the exponentially increasing demand for high potency drugs. Thus, to cater to the increasing demand, top-notch pharmaceutical companies such as Roche, GSK, Pfizer, and Merck are focused on strengthening their pipelines with novel therapeutic drugs, mainly for cancer treatment.

    

  • HPAPIs Segment, Revenue Generation Segment in Pharmaceutical Industry: In the pharma industry, HPAPI holds immense potential for revenue contribution. Nevertheless, manufacturers of HPAPIs must augment their technical and operational efficiencies for competitive advantage in this market. With the advancement of the biologics segment, it has resulted in increased application of HPAPIs for glaucoma, hormonal therapies, and targeted cancer therapies.